We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Wall Street's Insights Into Key Metrics Ahead of Johnson & Johnson (JNJ) Q3 Earnings
Read MoreHide Full Article
Analysts on Wall Street project that Johnson & Johnson (JNJ - Free Report) will announce quarterly earnings of $2.77 per share in its forthcoming report, representing an increase of 14.5% year over year. Revenues are projected to reach $23.74 billion, increasing 5.6% from the same quarter last year.
The consensus EPS estimate for the quarter has been revised 0.3% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Johnson & Johnson metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts forecast 'Sales- Innovative Medicine- WW' to reach $15.25 billion. The estimate indicates a change of +4.6% from the prior-year quarter.
The consensus estimate for 'Sales- MedTech- Total' stands at $8.35 billion. The estimate indicates a change of +5.8% from the prior-year quarter.
Based on the collective assessment of analysts, 'Sales- Innovative Medicine- Neuroscience- WW' should arrive at $2.06 billion. The estimate suggests a change of +17.4% year over year.
The collective assessment of analysts points to an estimated 'Sales- MedTech- Orthopaedics- WW' of $2.23 billion. The estimate points to a change of +1.7% from the year-ago quarter.
The consensus among analysts is that 'Sales- Innovative Medicine- Oncology- CARVYKTI- WW' will reach $515.54 million. The estimate indicates a year-over-year change of +80.3%.
According to the collective judgment of analysts, 'Sales- Innovative Medicine- Neuroscience- SPRAVATO- WW' should come in at $430.12 million. The estimate indicates a year-over-year change of +51.5%.
It is projected by analysts that the 'Sales- MedTech- Cardiovascular- Electrophysiology- WW' will reach $1.42 billion. The estimate indicates a year-over-year change of +10.6%.
Analysts predict that the 'Sales- MedTech- Cardiovascular- ABIOMED- WW' will reach $436.24 million. The estimate indicates a change of +20.5% from the prior-year quarter.
The average prediction of analysts places 'Sales- MedTech- Cardiovascular- Other Cardiovascular- WW' at $101.04 million. The estimate indicates a year-over-year change of +5.3%.
Analysts' assessment points toward 'Sales- MedTech- Orthopaedics- Hips- US' reaching $260.59 million. The estimate indicates a year-over-year change of +4.2%.
The combined assessment of analysts suggests that 'Sales- MedTech- Orthopaedics- Hips- International' will likely reach $133.94 million. The estimate indicates a year-over-year change of +2.3%.
Analysts expect 'Organic Sales Growth (Operational growth)' to come in at 4.9%. Compared to the present estimate, the company reported 6.3% in the same quarter last year.
Shares of Johnson & Johnson have experienced a change of +7.9% in the past month compared to the +4% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), JNJ is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Wall Street's Insights Into Key Metrics Ahead of Johnson & Johnson (JNJ) Q3 Earnings
Analysts on Wall Street project that Johnson & Johnson (JNJ - Free Report) will announce quarterly earnings of $2.77 per share in its forthcoming report, representing an increase of 14.5% year over year. Revenues are projected to reach $23.74 billion, increasing 5.6% from the same quarter last year.
The consensus EPS estimate for the quarter has been revised 0.3% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Johnson & Johnson metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts forecast 'Sales- Innovative Medicine- WW' to reach $15.25 billion. The estimate indicates a change of +4.6% from the prior-year quarter.
The consensus estimate for 'Sales- MedTech- Total' stands at $8.35 billion. The estimate indicates a change of +5.8% from the prior-year quarter.
Based on the collective assessment of analysts, 'Sales- Innovative Medicine- Neuroscience- WW' should arrive at $2.06 billion. The estimate suggests a change of +17.4% year over year.
The collective assessment of analysts points to an estimated 'Sales- MedTech- Orthopaedics- WW' of $2.23 billion. The estimate points to a change of +1.7% from the year-ago quarter.
The consensus among analysts is that 'Sales- Innovative Medicine- Oncology- CARVYKTI- WW' will reach $515.54 million. The estimate indicates a year-over-year change of +80.3%.
According to the collective judgment of analysts, 'Sales- Innovative Medicine- Neuroscience- SPRAVATO- WW' should come in at $430.12 million. The estimate indicates a year-over-year change of +51.5%.
It is projected by analysts that the 'Sales- MedTech- Cardiovascular- Electrophysiology- WW' will reach $1.42 billion. The estimate indicates a year-over-year change of +10.6%.
Analysts predict that the 'Sales- MedTech- Cardiovascular- ABIOMED- WW' will reach $436.24 million. The estimate indicates a change of +20.5% from the prior-year quarter.
The average prediction of analysts places 'Sales- MedTech- Cardiovascular- Other Cardiovascular- WW' at $101.04 million. The estimate indicates a year-over-year change of +5.3%.
Analysts' assessment points toward 'Sales- MedTech- Orthopaedics- Hips- US' reaching $260.59 million. The estimate indicates a year-over-year change of +4.2%.
The combined assessment of analysts suggests that 'Sales- MedTech- Orthopaedics- Hips- International' will likely reach $133.94 million. The estimate indicates a year-over-year change of +2.3%.
Analysts expect 'Organic Sales Growth (Operational growth)' to come in at 4.9%. Compared to the present estimate, the company reported 6.3% in the same quarter last year.
View all Key Company Metrics for Johnson & Johnson here>>>Shares of Johnson & Johnson have experienced a change of +7.9% in the past month compared to the +4% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), JNJ is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .